Law360, New York (September 29, 2014, 1:55 PM EDT) -- In Eli Lilly and Company v. Human Genome Sciences Inc., the English Patents Court (Justice Nicholas Roger Warren) recently gave its interpretation of the EU Court of Justice’s most recent decision in relation to supplementary protection certificates (“SPCs”). In doing so, the court confirmed that SPCs are available based on patents with claims that define the product in functional terms only; this is particularly important for patents relating to antibodies.
SPCs are a partial extension to the term of a patent. They are granted in relation to specific medicinal (or plant protection) products to compensate for the period of patent protection...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!